Vaginal cytological characteristics as a biomeasure of estrogenization in a communitybased population of older women

Similar documents
Elisa V. Bandera, MD, PhD

FemTouch Treatment for Improving Vulvovaginal Health

EVALUATION OF THE CERVICO-VAGINAL CYTOLOGY SMEARS IN POSTMENOPAUSAL WOMEN

Early detection and treatment for Esophageal Cancer in Africa

Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D

Is there an association between waist circumference and type 2 diabetes or impaired fasting glucose in US adolescents?

ANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION

PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals

Cytopathology. Robert M Genta Pathologie Clinique Université de Genève

A Study of Sexuality and Health among Older Adults in the United States

Measuring Sleep and Activity (Cycles) Using Wrist Actigraphy

International Journal of Biological & Medical Research

Anthem Central Region Clinical Claims Edit

Department of Sociology and Population Research Center, University of Chicago, Chicago, IL, USA

Iron status and novel risk factors for iron depletion in a diverse donor population

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

NAMS in the News 2016

Chapter Two Renal function measures in the adolescent NHANES population

Table of Contents. 1. Overview. 2. Interpretation Guide. 3. Staining Gallery Cases Negative for CINtec PLUS

North American Menopause Society (NAMS)

ASCCP Guideline Changes and Management of the Abnormal Pap Test Accurately Targeting Intervention

Genitourinary Symptoms of Menopause (GSM) Effects on Sexual Function

JMSCR Vol 06 Issue 06 Page June 2018

Atrophic Vaginitis. Mimi Clarke Secor CHAPTER 23

Sexual Health in Older Adults

NIH Public Access Author Manuscript Prev Med. Author manuscript; available in PMC 2014 June 05.

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention

1. What is your date of birth? Month Day Year

Overview of Wet Preps and Gram stains. Lorna Rabe Central Lab Magee-Womens Research Institute Pittsburgh, Pa

Pap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed???

Year: Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy

Therapeutic Cohort Results

NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR GENERAL PRACTICE

Menopause Symptoms and Management: After Breast Cancer

OBSTETRICS & GYNECOLOGY

One Day Hormone Check

Effects of Transdermal Estradiol in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial

The diagnostic category of atypical squamous cells of undetermined

Research Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms in Postmenopausal Women

One Day Hormone Check

January 15, 2009 (202) PROPOSALS TO IMPROVE CYTOLOGY PROFICIENCY TESTING REQUIRED BY THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988

Differences in Vaginal Bacterial Communities of Women in North America: Implications for disease diagnosis and prevention

Menopause 101. Sharzad Green, Pharm.D. Community Clinical Pharmacy

Why do I need any hormone replacement? What is Menopause? What symptoms are treated by estrogen Injections?

Hearing Physicians Views: HPV Immunization National Trends Survey (HPV HINTS)

Endocrinopathy and Leukocyte Telomere Length in HIV+ Individuals in the CARMA Cohort

Chapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence

SEXUAL PAIN Home messages, a summary from Presentations, moderated Posters and Podiums

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

5. Summary of Data Reported and Evaluation

ABSTRACT REPRODUCTIVE AND HORMONAL FACTORS IN RELATION TO LUNG CANCER AMONG NEPALI WOMEN

How to Select an Egg Donor

TITLE: Managing Menopausal Symptoms in Breast Cancer Survivors

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?

Cervicovaginal Flora Comparison of Conventional Pap Smears and a Liquid-Based Thin-Layer Preparation

Energy Based Therapies in Gynecology and Vaginal Health: Update on CO 2

chapter 4. The effect of oncogenic HPV on transformation zone epithelium

Vaginitis. Antibiotics Changes in hormone levels due to pregnancy, breastfeeding, or menopause Douching Spermicides Sexual intercourse Infection

Therapeutic Cohort Results

Cervical Cancer Prevention Month. January 2011 Morehouse College

Alexander Lankowski 1, Cedric Bien 1,2, Richard Silvera 1,2, Viraj Patel 1, Uriel Felsen 3, Oni Blackstock 1

Colposcopic Principles. Simon Leeson Consultant Obstetrician/ Gynaecologist Betsi Cadwaladr University Health Board UK

Sexual Dysfunction in Women with Breast Cancer: An Internet-Based Intervention. Leslie R. Schover, PhD Department of Behavioral Science

Therapeutic Cohort Results

LOCAL INFLAMMATION IN BREAST TISSUE AND MAMMOGRAPHIC DENSITY AMONG PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN

Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening

Cancer in Women. Lung cancer. Breast cancer

Estrogenic Activities of Pueraria candollei Grah. Tuberous Roots

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:

ClincialTrials.gov Identifier: sanofi-aventis. Sponsor/company:

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health

TABLE 1. Percentage of respondents to a national survey of young adults, by selected characteristics, according to gender, United States, 2009

Hormone Treatments and the Risk of Breast Cancer

10/11/2016. Richard J. Santen, MD. Disclosures. Key Question Regarding MHT and Breast Cancer Development. NAMS 2016 Translational Science Symposium

Colposcopy. Attila L Major, MD, PhD

New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology

2016. All Rights Reserved. 1

10/07/18. Conflict of interest statement

A Study of Physician Recommendations for Reversible Contraceptive Methods Using Standardized Patients

Research. Estrogen receptors have been identified

patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

5/5/2010 FINANCIAL DISCLOSURE. Abnormal Uterine Bleeding. Is This A Problem? About me % of visits to gynecologist

Situation of Obesity in Different Ages in Albania

Depression and Anxiety Relative Risks in Women Newly Diagnosed with Vulvovaginal Atrophy and Dyspareunia

Human Papillomavirus (HPV) Testing for Normal Cervical Cytology in Low-Risk Women Aged Years by Family Physicians

Menopause and HIV. Together, we can change the course of the HIV epidemic one woman at a time.

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

HEALTH CARE DISPARITIES. Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center

FEMININE INTIMATE CARE

Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol

Call for Appointments

Reproductive factors, age at maximum height, and risk of three histologic types of breast cancer

Hormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare

Community Health Advisors- Utilizing Lay Navigators. Michael Bertram, PhD, MBA Associate Director for Administration

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.

HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D

Methods and Baseline Cardiovascular Data From the Early Versus Late Intervention Trial With Estradiol Testing the Menopausal Hormone Timing Hypothesis

Relationship between Bone Mineral Density and Maturity Index in Cervical Smears, Serum Estradiol Levels and Body Mass Index

Transcription:

Vaginal cytological characteristics as a biomeasure of estrogenization in a communitybased population of older women Natalia Gavrilova, PhD 1,2 Annie Dude, MD, PhD 1 ; Joscelyn N. Hoffmann, AB 3 ; Martha K. McClintock, Ph.D. 2,3,4 L. Philip Schumm, MA 5 ; Stacy Tessler Lindau, MD, MAPP1,2, 4, 6 1 Pritzker School of Medicine, Department of Ob/Gyn, 2 Chicago Core on Biomeasures in Population-Based Research at the NORC-University of Chicago Center on Demography and Economics of Aging; 3 Institute for Mind and Biology, Departments of Psychology and Comparative Human Development 4; Comprehensive Cancer Center, 5 Department of Health Studies. and Department of Medicine (Gerontology), The University of Chicago

Disclosures Funding for this analysis: NIH 5R01AG021487 (Waite, PI) 1K23AG032870 (Lindau, PI) 5P30 AG 012857 (Waite, PI) The authors report no conflicts of interest Vaginal cytological characteristics 2

Background Vaginal mucosa is a target tissue for a broad spectrum of estrogens. Vaginal atrophy Indicates an estrogen deficit. May interfere with sexual and urinary function. Increases with age after menopause. Vaginal cytological characteristics 3

Estrogenized Vaginal Epithelium Layers superficial intermediate parabasal basal Atrophic Three Types (Or Stages) of Vaginal Epithelial Cells All scored to quantify estrogenization in the Vaginal Maturation Index The Vaginal Maturation Index quantifies the relative proportion of the vaginal parabasal (P), intermediate (I), and superficial (S) cells presented as % P / % I / % S. Sources: Mills, Histology for Pathologists. 3 rd Edition; LWW, 2006. Wheater, Functional Histology. 2 nd Edition; Bibbo, 1997

Quantifying Types of Desquamated Vaginal Epithelial Cells LESS ESTROGENIZED INTERMEDIATE MORE ESTROGENIZED Multichrome Papanicolaou stained cytology specimens obtained using vaginal self swabs in NSHAP Wave 1. McClintock lab: scored number and proportion of three epithelial cell types created a Maturation Index (MI). Vaginal cytological characteristics 5

Methods Vaginal cytological characteristics 6

National Social Life, Health and Aging Project (NSHAP) Wave 1 Nationally representative sample of people 57 to 85 years of age (Wave 1, 2005 06). Demographic, health, sexual, physical, and biological measures collected in the home. Vaginal swabs were self-collected and used for the following measures: Maturation Value (MV) Vaginal Candidiasis (yeast) Bacterial Vaginosis (BV) High Risk Human Papilloma Virus (HPV) The Institutional Review Boards of the University of Chicago and the National Opinion Research Center approved the protocol; all participants provided written documentation of informed consent. Vaginal cytological characteristics 7

Vaginal Swab Sample Collection Illustrated by Rachel Seelen

July 1, 2005 Cytopathology Lab University of Chicago Hospitals Chicago, IL January 2006 Papanicolaou Stain McClintock Lab Institute for Mind and Biology Chicago, IL July 20, 2005 Cells from swab to slide, MI Jordan Lab, Magee Women s Hospital Pittsburgh, PA July 6, 2005 BV, Yeast, HPV

Vaginal swab collection Flow chart of vaginal swabs collection Vaginal cytological characteristics 10

Successful Vaginal Swab Collection 66% of women agreed to provide a self-administered vaginal swab specimen (N = 1,028 of 1,550) 85% were adequate for MI scores (N = 869 of 1,028) Non-responders to the vaginal swab protocol were : older <HS graduate less likely to report a recent pelvic examination, menopausal prescription hormone use Lindau et al., 2008 Vaginal cytological characteristics 11

The Maturation Value is a clinical measure of vaginal estrogenization derived from the Maturation Index Maturation Value = 1.0 x % superficial cells + 0.5 x % intermediate cells + 0.0 x % parabasal cells Potential range: 0 100 Vaginal cytological characteristics 12

Maturation Value of the Vaginal Epithelium suggested by Meisels in Acta Cytologica, 1965, who called it an estrogenic value a bioassay of functionally active estrogens counteracted by progesterone provides an integrated measure of hormonal bioactivity over many days based only on intermediate and superficial epithelial cells Vaginal cytological characteristics 13

Hypotheses Vaginal epithelial estrogenization among post-menopausal women will be: Inversely associated with age and years since menopause Rationale: Results from historical clinical study (Meisels, 1966) Positively associated with obesity Rationale: Abdominal fat tissue can produce estrone Higher in African American women compared to other racial and ethnic groups. Rationale: Existing publications (McTernan, Wu, 2008; Setiawan, et al., 2006) and our own results from the NSHAP study suggest that African-American women have higher levels of free estradiol Positively associated with sexual function Vaginal cytological characteristics 14

Clinical Benchmark Study of Canadian Gynecology Patients Maturation Value 45 40 35 30 25 20 15 10 5 0 Meisels, 1966 1,124 728 498 105 269 37 55-59 60-64 65-69 70-74 75-79 > 80 Age (years) Reference: Meisels A. Menopause - A cytohormonal study. Acta Cytol. 1966;10(1):49-55 Vaginal cytological characteristics 15

Results Vaginal cytological characteristics 16

Distribution of Maturation Value in NSHAP Wave 1 Vaginal cytological characteristics 17

Maturation Value: (A) Age and (B) Hormone Therapy Use Use Vaginal cytological characteristics 18

Testing hypotheses using the maturation value #1: Linear regression model to determine correlates (X) of the maturation value (Y). Y = X 1 k X k Maturation value = hormone therapy + + k X k Other covariates tested Demographic characteristics: Age, Race, Ethnicity, Education Health characteristics: Oophorectomy, Obesity, Hormone therapy past 12 mo, Sexual activity Vaginal cytological characteristics 19

Multiple linear regression model of the maturation value (MV), NSHAP Wave 1 Covariate Parameter estimate 95% CI P value Age 0.08 0.21, 0.38 0.59 Years since last menstrual period 0.10 0.05, 0.24 0.19 African American race (vs white, ref.) 8.58 5.07, 12.08 <0.001 Some college/associates education (vs HS graduate, ref.) 2.64 5.25, 0.02 0.048 HT use in last 12 months 12.44 9.19, 15.70 <0.001 Waist circumference (inches) 0.58 0.34, 0.82 <0.001 Effects of other covariates in the model (Bilateral oophorectomy, Sexual activity past 12 months and Hispanic ethnicity) turned out to be non-significant. Vaginal cytological characteristics 20

#2: Logistic regression using the standardized maturation value as an independent variable (X) to predict symptoms/conditions (Y). Prob.(symptom) = 1 e 1 ( 0 1maturation _ value 2age 3HT ) Symptoms/Conditions examined: Sexual Activity Pain during sex Vaginal dryness during sex Urinary incontinence Bacterial vaginosis, Yeast infection High risk HPV Other urinary problems,

Logistic regression models of clinical and behavioral outcomes on standardized maturation value (MV), NSHAP Wave 1 Outcome Odds ratio 95% CI P value Sexual activity (within the past 12 0.88 0.73, 1.05 0.15 months) Pain during sex (for sexually active 0.80 0.55, 1.17 0.24 women) Problems lubricating (for sexually 0.61 0.46, 0.82 0.001 active women) Current bacterial vaginosis 1.54 1.26, 1.88 <0.001 Current yeast infection 1.56 1.15, 2.13 0.005 High risk HPV 1.08 0.78, 1.51 0.63 Maturation value standardized by subtracting the sample mean and dividing by the sample standard deviation. Vaginal cytological characteristics 22

Conclusions Vaginal cytological characteristics 23

Hypotheses tested Vaginal epithelial estrogenization among postmenopausal women will be: Inversely associated with age and years since menopause? No Positively associated with abdominal obesity: Yes Higher in African American women compared to other racial and ethnic groups: Yes Positively associated with sexual function: Yes, mostly Vaginal cytological characteristics 24

Summary: Maturation value is an integrative biomeasure of estrogenization of women, useful for analyses of health and sexuality In contrast to 1960s benchmark clinical data, current population estimates of vaginal estrogenization are higher and do not exhibit a decline with age. Differences may be explained in part by studying different populations: Women who come to a clinic Representative sample of community-dwelling older women in the US. Vaginal cytological characteristics 25

Study limitations Selection bias: women who provided a vaginal specimen were, on average: younger more educated more likely to have urinary problems more likely to use HT Vaginal cytological characteristics 26

Acknowledgements NIH 5R01AG021487 (Waite, PI) 1K23AG032870-01A1 (Lindau, PI) 5P30 AG 012857 (Waite, PI) National Institute on Aging Office of Women's Health Research Office of AIDS Research Office of Behavioral and Social Sciences Research Equipment, supplies, services donated or provided at reduced cost for data collection by: OraSure, Sunbeam, A&D Medical/LifeSource, Wilmer Eye Institute at the John Hopkins Bloomberg School of Public Health, Schleicher & Schuell Bioscience, BioMerieux, Roche Diagnostics, Digene, and Richard Williams Vaginal cytological characteristics 27

Additional information can be found at the CCBAR website http://biomarkers.uchicago.edu/ Vaginal cytological characteristics 28

Chicago Core on Biomarkers in Population Based Aging Research CCBAR website http://biomarkers.uchicago.edu/